1309P A genomic scar based signature (HRDsig) and biallelic BRCA alterations identify a homologous recombination deficiency (HRD) phenotype of non-small cell lung cancer (NSCLC) potentially actionable to the PARP inhibitor rucaparib: Post-hoc analysis of lung-MAP substudy S1900A
Jonathan W. Riess(University of California Davis Medical Center), Karen Kelly(Cancer Research Center), M.W. Redman(Fred Hutch Cancer Center), E.S. Sokol(Foundation Medicine (United States)), Hossein Borghaei(Fox Chase Cancer Center), Megan Baumgart(University of Rochester), Linda Corum(The University of Kansas Cancer Center), B. Faller(Heartland Cancer Research), Raymond U. Osarogiagbon, Karen L. Reckamp(Memorial Sloan Kettering Cancer Center), Paul Wheatley‐Price(University of Ottawa), Martin J. Edelman(Fox Chase Cancer Center), Gordan Srkalović(Regional Cancer Center), David Kozono(Brigham and Women's Hospital), Jieling Miao(Fred Hutch Cancer Center), D.R. Gandara(UC Davis Comprehensive Cancer Center), Ashok Gowda(Memorial Hospital of South Bend), Jhanelle E. Gray(Moffitt Cancer Center), L. Villaruz(UPMC Hillman Cancer Center), Roy S. Herbst(Smilow Cancer Hospital)
Cited by 2
Related Papers
Lung Cancer
|New England Journal of Medicine|2008|2.4k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
|Journal of Clinical Oncology|2004|1.7k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k